David Meeker has brought a tremendous amount of experience and an innovative spirit to the Board of Prize4Life." Said Avi Kremer, Prize4Life’s CEO and co-founder. "His expertise has been integral to the successes our organization
Cambridge, MA (PRWEB) October 28, 2011
Prize4Life, a non-profit organization dedicated to accelerating the discovery of treatments and a cure for Amyotrophic Lateral Sclerosis (ALS), is pleased to congratulate David Meeker on the recent announcement that he will be named the Chief Executive Officer of Genzyme. Meeker also serves as a member of Prize4Life’s Board of Directors and was previously a member of the organization’s Scientific Advisory Board.
“David Meeker has brought a tremendous amount of experience and an innovative spirit to the Board of Prize4Life. His expertise has been integral to the successes our organization has enjoyed over the past five years, most notably the awarding of our $1M ALS Biomarker Prize,” said Avi Kremer, Prize4Life’s CEO and co-founder. “We are proud to extend our congratulations to Dr. Meeker and Genzyme.”
David Meeker was named Chief Operating Officer of Genzyme in 2009. Prior to that, he was the Executive Vice President of Therapeutics, Biosurgery & Transplant at Genzyme. Before joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and assistant professor of medicine at Ohio State University.
Genzyme agreed to be acquired by French pharmaceutical company Sanofi for $20 billion in February. Dr. Meeker worked closely with former CEO Henri Termeer, who led the acquisition negotiations.
Prize4Life is a nonprofit organization dedicated to accelerating the discovery of treatments and a cure for ALS by using powerful incentives to attract new people and drive innovation. Prize4Life was founded in 2006 by Avi Kremer, who was diagnosed with ALS at the age of 29 while attending Harvard Business School. The organization aims to use prizes to bring new minds and new money into the fight against ALS and focus efforts on specific outcomes that will bridge the gap between academic research and the development of treatments and a cure.